CARIBOU BIOSCIENCES INC. - COMMON STOCK

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

24 Apr 2025 16:15:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

10 Mar 2025 16:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

18 Feb 2025 16:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025

12 Jan 2025 19:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

07 Jan 2025 16:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer

02 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

20 Nov 2024 16:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Third Quarter 2024 Financial Results and  Provides Business Update

06 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024

25 Sep 2024 09:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML

03 Sep 2024 08:01:11 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

26 Aug 2024 16:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

12 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update

06 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

09 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

02 Jun 2024 19:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

30 May 2024 16:01:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

07 May 2024 16:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

01 May 2024 16:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 10:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

15 Apr 2024 09:00:00 By Nasdaq GlobeNewswire